Share this article
Share this article
EXTON, Pa., Feb. 10, 2021 /PRNewswire/ Despite the potential for setbacks brought forth by the COVID-19 pandemic, Amgen recently reported strong year-over-year growth for their newly acquired psoriasis (PSO) and psoriatic arthritis (PsA) agent, Otezla.
1 In late 2019, the brand was sold to Amgen in order to clear the path for Bristol-Myers Squibb s acquisition of Celgene, considering future regulatory conflicts with BMS pipeline psoriasis drug, deucravacitinib, an oral TYK2 inhibitor anticipated to be in direct competition with Otezla.
Amgen s purchase of Otezla strengthens the company s long-standing immunology portfolio, including TNF inhibitor, Enbrel, which has been approved in RA for over two decades and also holds a dual PSO/PsA indication. However, according to ongoing feedback collected from US dermatologists and rheumatologists included in Spherix s
Share this article
Share this article
CARY, N.C., Jan. 27, 2021 /PRNewswire/ After more than two decades of dedication to advance the prevention, diagnosis, and treatment of cancer, Dr. Martin J. Murphy has retired from the Board of Directors of the CEO Roundtable on Cancer. The Board immediately elected him Director Emeritus.
Dr. Murphy was instrumental in launching the CEO Roundtable on Cancer in 2001 at the request of President George H.W. Bush who challenged him to engage action-oriented chief executives to do something more about cancer prevention, diagnosis, and treatment within your own family as well as within your corporate family.
These updates are republished press releases and communications from members of the Science|Business Network
Amgen CEO: Greater U.S.-China collaboration will accelerate fight against cancer
Last month, Amgen CEO Bob Bradway helped kick off a high-level roundtable discussion focused on accelerating cancer research through greater collaboration between the U.S. and China. Held November 18 as part of the Bloomberg New Economy Forum, the Moonshot Roundtable discussion was co-facilitated by the Honorable Kevin Rudd, President of the Asia Society Policy Institute and former Prime Minister of Australia, and Dr. Bob Li, Physician Ambassador to China and Asia-Pacific at Memorial Sloan Kettering Cancer Center. The session brought together senior leaders from industry, academia and government.